FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIR (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC) : a multicentre randomised phase iii trial from the Hellenic Oncology Research Group (HORG)
- Author
- SOUGLAKOS, J1 ; ANDROULAKIS, N1 ; KALYKAKI, A1 ; SAMONIS, G1 ; MAVROUDIS, D1 ; GEORGOULIAS, V1 ; SYRIGOS, K2 ; POLYZOS, A3 ; ZIRAS, N4 ; ATHANASIADIS, A5 ; KAKOLYRIS, S6 ; TSOUSIS, S7 ; KOUROUSSIS, Ch8 ; VAMVAKAS, L1
[1] Deportment of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, Heraklion, Crete 71110, Greece
[2] Third Department of Internal Medicine, School of Medicine, University of Athens, 'Sotiria' General Hospital of Athens, Greece
[3] Department of Propedeutic Medicine, Medical Oncology Unit, School of Medicine, University of Athens, 'Laikon' General Hospital of Athens, Greece
[4] First Department of Medical Oncology, 'METAXA'S' Anticancer Hospital of Athens, Greece
[5] Department of Medical Oncology, General Hospital of Larissa, Greece
[6] Deportment of Medical Oncology, University General Hospital of Alexandroupoli, Greece
[7] Department of Medical Oncology, 'Venizelion' General Hospital of Heraklion, Greece
[8] First Department of Medical Oncology, 'Theagenion' Anticoncer Hospital of Thessaloniki, Greece - Source
British journal of cancer. 2006, Vol 94, Num 6, pp 798-805, 8 p ; ref : 32 ref
- CODEN
- BJCAAI
- ISSN
- 0007-0920
- Scientific domain
- Medical oncology
- Publisher
- Nature Publishing Group, Basingstoke
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- FOLFOXIRI colorectal cancer metastatic
- Keyword (fr)
- Anticancéreux Cancer colorectal Cancérologie Essai clinique phase III Essai clinique Etude comparative Fluorouracil Folinate de calcium Irinotécan Métastase Oxaliplatine Recherche Stade avancé Tumeur maligne Acide folinique Camptothécine dérivé Inhibiteur topoisomerase I Pyrano indolizino quinoléine dérivé Traitement première intention Agent alkylant Antimétabolite Appareil digestif pathologie Côlon pathologie DNA topoisomerase Enzyme Fluoropyrimidine dérivé Inhibiteur enzyme Intestin pathologie Isomerases Methyltransferases Platine II Complexe Pyrimidine dérivé Rectum pathologie Thymidylate synthase Transferases
- Keyword (en)
- Antineoplastic agent Colorectal cancer Cancerology Phase III trial Clinical trial Comparative study Fluorouracil Calcium folinate Irinotecan Metastasis Oxaliplatin Research Advanced stage Malignant tumor Folinic acid First line treatment Alkylating agent Antimetabolic Digestive diseases Colonic disease DNA topoisomerase Enzyme Fluoropyrimidine derivatives Enzyme inhibitor Intestinal disease Isomerases Methyltransferases Platinum II Complexes Pyrimidine derivatives Rectal disease Thymidylate synthase Transferases
- Keyword (es)
- Anticanceroso Cancer de colon y recto Cancerología Ensayo clínico fase III Ensayo clínico Estudio comparativo Fluorouracilo Folinato cálcico Irinotecán Metástasis Oxaliplatino Investigación Estadio avanzado Tumor maligno Tratamiento primer línea Agente alquilante Antimetabólito Aparato digestivo patología Colón patología DNA topoisomerase Enzima Fluoropirimidina derivado Inhibidor enzima Intestino patología Isomerases Methyltransferases Platino II Complejo Pirimidina derivado Recto patología Thymidylate synthase Transferases
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B13 Gastroenterology. Liver. Pancreas. Abdomen / 002B13B Stomach. Duodenum. Small intestine. Colon. Rectum. Anus / 002B13B01 Tumors
- Discipline
- Gastroenterology. Liver. Pancreas. Abdomen Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 17642379
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1038/sj.bjc.6603011 
https://dx.doi.org/10.1038/sj.bjc.6603011
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6603011\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:278:\"FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIR (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC) : a multicentre randomised phase iii trial from the Hellenic Oncology Research Group (HORG)\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"94\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"798\";s:8:\"\u0000*\u0000epage\";s:3:\"805\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"SOUGLAKOS\";s:10:\"\u0000*\u0000aufirst\";s:1:\"J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:14:\"ANDROULAKIS, N\";i:1;s:11:\"KALYKAKI, A\";i:2;s:10:\"SAMONIS, G\";i:3;s:12:\"MAVROUDIS, D\";i:4;s:14:\"GEORGOULIAS, V\";i:5;s:10:\"SYRIGOS, K\";i:6;s:10:\"POLYZOS, A\";i:7;s:8:\"ZIRAS, N\";i:8;s:15:\"ATHANASIADIS, A\";i:9;s:12:\"KAKOLYRIS, S\";i:10;s:10:\"TSOUSIS, S\";i:11;s:14:\"KOUROUSSIS, Ch\";i:12;s:11:\"VAMVAKAS, L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:278:\"FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIR (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC) : a multicentre randomised phase iii trial from the Hellenic Oncology Research Group (HORG)\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6603011\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:278:\"FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIR (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC) : a multicentre randomised phase iii trial from the Hellenic Oncology Research Group (HORG)\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"94\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"798\";s:8:\"\u0000*\u0000epage\";s:3:\"805\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"SOUGLAKOS\";s:10:\"\u0000*\u0000aufirst\";s:1:\"J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:14:\"ANDROULAKIS, N\";i:1;s:11:\"KALYKAKI, A\";i:2;s:10:\"SAMONIS, G\";i:3;s:12:\"MAVROUDIS, D\";i:4;s:14:\"GEORGOULIAS, V\";i:5;s:10:\"SYRIGOS, K\";i:6;s:10:\"POLYZOS, A\";i:7;s:8:\"ZIRAS, N\";i:8;s:15:\"ATHANASIADIS, A\";i:9;s:12:\"KAKOLYRIS, S\";i:10;s:10:\"TSOUSIS, S\";i:11;s:14:\"KOUROUSSIS, Ch\";i:12;s:11:\"VAMVAKAS, L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:278:\"FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIR (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC) : a multicentre randomised phase iii trial from the Hellenic Oncology Research Group (HORG)\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6603011\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6603011\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:278:\"FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIR (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC) : a multicentre randomised phase iii trial from the Hellenic Oncology Research Group (HORG)\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"94\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"798\";s:8:\"\u0000*\u0000epage\";s:3:\"805\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"SOUGLAKOS\";s:10:\"\u0000*\u0000aufirst\";s:1:\"J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:14:\"ANDROULAKIS, N\";i:1;s:11:\"KALYKAKI, A\";i:2;s:10:\"SAMONIS, G\";i:3;s:12:\"MAVROUDIS, D\";i:4;s:14:\"GEORGOULIAS, V\";i:5;s:10:\"SYRIGOS, K\";i:6;s:10:\"POLYZOS, A\";i:7;s:8:\"ZIRAS, N\";i:8;s:15:\"ATHANASIADIS, A\";i:9;s:12:\"KAKOLYRIS, S\";i:10;s:10:\"TSOUSIS, S\";i:11;s:14:\"KOUROUSSIS, Ch\";i:12;s:11:\"VAMVAKAS, L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:278:\"FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIR (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC) : a multicentre randomised phase iii trial from the Hellenic Oncology Research Group (HORG)\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6603011\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:278:\"FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIR (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC) : a multicentre randomised phase iii trial from the Hellenic Oncology Research Group (HORG)\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"94\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"798\";s:8:\"\u0000*\u0000epage\";s:3:\"805\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"SOUGLAKOS\";s:10:\"\u0000*\u0000aufirst\";s:1:\"J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:14:\"ANDROULAKIS, N\";i:1;s:11:\"KALYKAKI, A\";i:2;s:10:\"SAMONIS, G\";i:3;s:12:\"MAVROUDIS, D\";i:4;s:14:\"GEORGOULIAS, V\";i:5;s:10:\"SYRIGOS, K\";i:6;s:10:\"POLYZOS, A\";i:7;s:8:\"ZIRAS, N\";i:8;s:15:\"ATHANASIADIS, A\";i:9;s:12:\"KAKOLYRIS, S\";i:10;s:10:\"TSOUSIS, S\";i:11;s:14:\"KOUROUSSIS, Ch\";i:12;s:11:\"VAMVAKAS, L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:278:\"FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIR (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC) : a multicentre randomised phase iii trial from the Hellenic Oncology Research Group (HORG)\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.bjc.6603011\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:278:\"FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIR (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC) : a multicentre randomised phase iii trial from the Hellenic Oncology Research Group (HORG)\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. J. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"94\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"798\";s:8:\"\u0000*\u0000epage\";s:3:\"805\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"SOUGLAKOS\";s:10:\"\u0000*\u0000aufirst\";s:1:\"J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:13:{i:0;s:14:\"ANDROULAKIS, N\";i:1;s:11:\"KALYKAKI, A\";i:2;s:10:\"SAMONIS, G\";i:3;s:12:\"MAVROUDIS, D\";i:4;s:14:\"GEORGOULIAS, V\";i:5;s:10:\"SYRIGOS, K\";i:6;s:10:\"POLYZOS, A\";i:7;s:8:\"ZIRAS, N\";i:8;s:15:\"ATHANASIADIS, A\";i:9;s:12:\"KAKOLYRIS, S\";i:10;s:10:\"TSOUSIS, S\";i:11;s:14:\"KOUROUSSIS, Ch\";i:12;s:11:\"VAMVAKAS, L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:278:\"FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIR (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC) : a multicentre randomised phase iii trial from the Hellenic Oncology Research Group (HORG)\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
